Moderna (MRNA) shares plunged after a partial leak showed results for the company's cancer vaccine trial. As Alison Kosik points out, the results were positive but weren't enough for investors. She walks through what Wall Street has access to from the leaks and the astronomical expectations priced into the stock and how it has corrected since. Tim Biggam offers an example options trade for Moderna.